- Expansion adds modules covering biologics, exosomes, MSCs, NK cells, dendritic cells, immunotherapy, CAR-T science, peptide medicine, and longevity medicine
- Next generation of ISSCA’s Online Academy broadens physician access to regenerative medicine education
- Curriculum growth complements ISSCA’s in-person conference and certification programs
FOR IMMEDIATE RELEASE
MIAMI, FL — The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced the next generation of its Online Academy, adding curriculum modules covering biologics, exosomes, mesenchymal stromal/stem cells (MSCs), Natural Killer cells, dendritic cells, immunotherapy, CAR-T cell science, peptide medicine, longevity medicine, and other emerging regenerative technologies.
The expanded Academy is designed to give physicians outside ISSCA’s in-person conference markets ongoing access to structured, updated regenerative-medicine education. ISSCA said the expansion reflects sustained physician demand for digital-first education formats alongside its conference and certification programming.
The organization was clear that Online Academy modules constitute physician education and do not themselves authorize any physician to administer a particular therapy — authorization remains governed by each physician’s own licensure and applicable local regulation.
“Not every physician can travel to a conference for every new modality,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “Expanding the Online Academy is how ISSCA keeps a much larger physician population current, between the in-person events we run around the world.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About ISSCA
The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), was founded in 2009 and has trained more than 12,000 physicians across more than 45 countries in regenerative medicine, longevity medicine, and related disciplines through certifications, fellowships, conferences, and online education.
